Literature DB >> 2767013

Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans.

E Ben-Menachem1.   

Abstract

A study was conducted to assess the impact of single dosing and different dosing intervals of vigabatrin [gamma vinyl GABA (GVG)] in 11 patients with drug-resistant complex partial seizures. Cerebrospinal fluid (CSF) concentrations of total GABA, free GABA, homocarnosine, homovanillic acid (HVA), GVG, and 5-hydroxyindolacetic acid were measured up to seven days after a single dose. GVG levels were maximal within 24 h, suggesting that GVG acts to inhibit GABA-transaminase, and may also increase biogenic amines.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2767013     DOI： 10.1111/j.1528-1157.1989.tb05826.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN： 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

Review 2.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

3.  Stereoselective interaction of thiopentone enantiomers with the GABA(A) receptor.

Authors:  D J Cordato; M Chebib; L E Mather; G K Herkes; G A Johnston
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 4.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

5.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

Review 6.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

7.  Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo.

Authors:  D L Rothman; O A Petroff; K L Behar; R H Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

8.  Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.

Authors:  Richard J Shannon; Ivan Timofeev; Jürgens Nortje; Peter J Hutchinson; Keri L H Carpenter
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.